Real World Evidence Study
Stallergenes Greer is sponsoring the BREATH (Bringing Real-World Evidence to Allergy Treatment for Health) real-world evidence program. This program is designed to gather real-world data about the benefits of allergy immunotherapy (AIT) for allergic patients.
The BREATH studies review prescription data for a variety of AIT products, including Stallergenes Greer’s products and deepens our knowledge and understanding of real-life patient outcomes.
The first BREATH studies have been designed by a dedicated scientific committee of allergologists, pharmacoepidemiologists and pneumologists from multiple countries, and utilize large prescription databases, visualizing real-life patient treatments.These databases provide us with the unique opportunity to follow a long patient treatment history. Patients can be faced with a life-long burden of disease1, therefore providing data on the long-term impact of AIT for allergy is paramount.
Rather than being a replacement for AIT Real Clinical Trial studies (RCT), which are gold standard studies, Real World Evidence complements clinical trial studies by investigating variables that are typically controlled for or excluded (such as comorbidities, lifestyles or demographics), are cost-restrictive, or where multiple study arms are not possible. It can provide us with additional insights, from both the physician and the patient perspectives2,3.
1. Papadopoulos NG, et al. Clin Transl Allergy. 2012. 2:21.
2. Sherman R, et al. N Engl J Med, 2016. 375(23), 2293-2297.
3. Mahajan R. Int J App Basic Med Res. 205. 5(2), 82.